This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change ABBVNegative Net Change
pharmaceuticals vaccines
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
JNJNegative Net Change PFENegative Net Change MRKNegative Net Change ILMNNegative Net Change MRNANegative Net Change GMENegative Net Change BNTXNegative Net Change
finance medical vaccines
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
PFENegative Net Change MRKNegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechnology vaccines
How Disruptive Will Omicron Be? Global Week Ahead
by John Blank
How disruptive will the Omicron COVID variant prove to be for the world economy? That's a lead question U.S. and Global stock markets grapple with.
JDNegative Net Change TTDKYPositive Net Change AUOTYPositive Net Change
emerging-markets vaccines
Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab
by Zacks Equity Research
Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.
GSKNegative Net Change JNJNegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical vaccines
Should You Buy HP (HPQ) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
HPQPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron
by Kinjel Shah
The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
REGNNegative Net Change JNJNegative Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
pharmaceuticals vaccines
Powell Vows to Speed-Up Taper, Market Falls
by Mark Vickery
Shares plummeted for the second trading day in the last three, with the Dow finishing down -652 points, -1.86%, the S&P 500 -1.90% and the Nasdaq dropping -1.55% on the day.
CRMPositive Net Change ADPNegative Net Change MRNANegative Net Change HPEPositive Net Change
earnings finance vaccines
Moderna ETFs Rallying on COVID-19 Vaccine News to Combat Omicron
by Sweta Jaiswal, FRM
Moderna has been rallying amid concerns surrounding the omicron variant, which has led to possibilities of a rise in demand for COVID-19 vaccines and boosters.
MRNANegative Net Change IBBNegative Net Change BBHNegative Net Change IDNAPositive Net Change
biotechs etfs vaccines
Reversal on Omicron Prospects Send Markets Down
by Mark Vickery
Moderna's (MRNA) Stephane Bancel told the Financial Times that the scientists he's been talking to say fighting Omicron is "not going to be good."
MRNANegative Net Change QQQPositive Net Change SPYPositive Net Change DIANegative Net Change
vaccines
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
medical vaccines
Nice Relief Rally on Biotech Assurances, Home Sales Data
by Mark Vickery
The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.
MRNANegative Net Change NVAXNegative Net Change
vaccines
Nice Relief Rally on Biotech Assurances, Home Sales Data
by Mark Vickery
The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.
MRNANegative Net Change NVAXNegative Net Change
vaccines
Will Bond Tapering Speed Up? Hold? Global Week Ahead
by John Blank
Macro data out in the Global Week Ahead could provide the spark: one that re-ignites risk-free U.S. Treasury bond market rates, heedless of this fresh COVID variant worry.
HDNegative Net Change JDNegative Net Change
business-services emerging-markets finance vaccines
Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential
by Zacks Equity Research
Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.
GSKNegative Net Change NVAXNegative Net Change DTILPositive Net Change ISEEPositive Net Change
biotechs medical vaccines
Will Cyber Monday Rescue Holiday Shopping from Omicron Fears?
by Mark Vickery
Pre-market futures this morning are buoyant, indicating market participants may have overreacted to the Friday news.
AMZNPositive Net Change ADPNegative Net Change PFENegative Net Change
pharmaceuticals retail vaccines
Fluor (FLR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FLRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Black Friday Meets "Black Friday:" New Covid Variant Hits Markets
by Mark Vickery
A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.
PFENegative Net Change UALNegative Net Change MRNANegative Net Change TRIPNegative Net Change NCLHPositive Net Change ZMNegative Net Change PTONNegative Net Change BNTXNegative Net Change
consumer-discretionary consumer-staples medical pharmaceuticals vaccines
Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe
JNJNegative Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
pharmaceuticals vaccines
Sierra Wireless (SWIR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SWIRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pulse Biosciences, Inc (PLSE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PLSENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Five Below (FIVE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FIVEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Financial Corp. (THFF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
THFFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Accuray (ARAY)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ARAYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
J&J (JNJ) Gets First Full Approval for COVID Jab in Canada
by Zacks Equity Research
Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.
JNJNegative Net Change PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change
pharmaceuticals vaccines